GlassScriptPhysician profile
Kimberly M Hoste
NPI 1285245969
$2,156.39
in general payments reported to CMS, 2019-2025
33 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2023: $128 · 2024: $55.77 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $335.13 | 2021-2025 | |
| Lilly USA, LLC | $316.53 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $239.94 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $126.35 | 2021-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $122.43 | 2025 | |
| Exact Sciences Corporation | $112.16 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $110.75 | 2025 | Rexulti |
| Pfizer INC. | $85.55 | 2025 | |
| Astellas Pharma US INC | $66.80 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.71 | 2021 | |
| Insulet Corporation | $52.96 | 2025 | Omnipod |
| Sumitomo Pharma America, INC. | $44.15 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.22 | 2025 | Caplyta |
| Boston Scientific Corporation | $35.65 | 2021 | |
| Glaxosmithkline, LLC. | $34.84 | 2021-2025 | Trelegy Ellipta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $34.34 | 2021-2025 | Minimed 780g |
| Merck Sharp & Dohme LLC | $33.41 | 2021-2025 | M-M-R II, Capvaxive, Varivax |
| Inspire Medical Systems, INC. | $33.36 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.36 | 2021-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $28.55 | 2025 | |
| Gilead Sciences, INC. | $22.09 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.69 | 2025 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.13 | 2025 | Lifevest |
| Allergan, INC. | $19.06 | 2021 | |
| Upsher-Smith Laboratories LLC | $18.84 | 2021 | |
| Phadia US INC. | $17.52 | 2025 | Immunocap |
| Organon LLC | $16.73 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.66 | 2025 | |
| Corcept Therapeutics | $14.10 | 2025 | Korlym |
| Seqirus USA INC | $13.58 | 2021 | |
| Vistapharm, INC. | $13.53 | 2021 | |
| Hologic Sales and Service, LLC | $13.13 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Hoste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.